Intravenous human plasma-derived augmentation therapy in α1-antitrypsin deficiency: From pharmacokinetic analysis to individualizing therapy

Annals of Pharmacotherapy

Volumn 42, Issue 5, 2008, Pages 640-646

  Zamora, Nuria Padullés ^a   Pla, Rafael Vidal ^a   Del Rio, Pilar Gispert ^a   Margaleff, Rosendo Jardi ^a   Frias, Francisco Rodriguez ^a   Ronsano, Jose Bruono Montoro ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

1 antitrypsin; Emphysema; Replacement therapy

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; AGE DISTRIBUTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; GENETIC DISORDER; HUMAN; MALE; PATIENT ASSESSMENT; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SEX RATIO; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 42949085601     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K505     Document Type: Article

References (21)

1. Tobin MJ, Cook PJ, Hutchison DC. Alpha-1-antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983;77:14-27.
2. Sandhaus RA. Elastase may play a central role in the neutrophil migration through connective tissue. In: Taylor JC, Mittman C, eds. Pulmonary emphysema and proteolysis. Orlando, FL: Academic Press, 1997:227-33.
3. Larsson C. Natural history and life expectancy in severe A-1 antitrypsin deficiency, PiZ. Acta Med Scand 1978;204:345-51.
4. Schwaiblmair M, Vogelmeier C. Alpha 1-antitrypsin. Hope on the horizon for emphysema sufferers? Drugs Aging 1998;12:429-40.
5. Schmidt EW, Rasche B, Ulmer WT, et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease. Am J Med 1988;84:63-9.
6. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha 1-antitrypsin. Am J Respir Clin Care Med 2003;168:818-900.
7. Brantly ML, Wittes JT, Vogelmeier CF, Hubbard RC, Fells GA, Crystal RG. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 1991;100:703-8.
8. Crystal RG. Alpha-1-antitrypsin deficiency, emphysema and liver disease: genetic basis and strategies for therapy. J Clin Invest 1998;85: 1343-52.
9. Soy D, De la Roza C, Lara B, Esquinas C, Torres A, Miravitlles M. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax 2006;61:1059-64.
10. Piitulainen E, Bernspang E, Bjorkman S, et al. Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha-1-antitrypsin. Eur J Clin Pharmacol 2003; 59:151-6.
11. Stoller J. Key current clinical issues in alpha-1-antitrypsin deficiency. Respir Care 2003;48:1216-21.
12. Sandhaus R. Alpha-1-antitrypsin deficiency. 6: new and emerging treatments for alpha-1-antitrypsin deficiency. Thorax 2004;59:904-9.
13. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316:1055-62.
14. Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha-1-antitrypsin infusion in alpha-1-antitrypsin deficiency. Chest 1997;112:607-13.
15. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha-1-antitrypsin deficiency. JAMA 1988;260:1259-64.
16. Vidal R, Padullés N, Sala F, Jardí R, Rodríguez F, Montoro JB. [Pharmacokinetics of alpha-1-antitrypsin replacement therapy in severe congenital emphysema] Spanish. Arch Bronconeumol 2006;42:553-6.
17. Vidal R, Blanco I, Casas F, Jardí R, Miravitlles M. [Diagnose and treatment of alpha-1-antitrypsin deficiency] Spanish. Arch Bronconeumol 2006;42:645-59.
18. Laurell CS, Nosslin B, Jeppsson JO. Catabolic rate of AAT of Pi type M and Z in man. Clin Sci Mol Med 1977;52:457-61.
19. Jones AE, Vergalla J, Steer CJ, Bradley-Moore PR, Vierling JM. Metabolism of intact and desialylated alpha 1-antitrypsin. Clin Sci Mol Med 1978;55:139-48.
20. Makimo S, Reed CE. Distribution and elimination of exogenous AAT. J Lab Clin Med 1970;75:742-5.
21. Constans J, Carles P, Boneu A, et al. Clinical pharmacokinetics of alpha-1-antitrypsin in homozygous PiZ deficient patients. Clin Pharmacokinet 1992;23:161-8.